GenScript Biotech Reports Full Year 2020 Financial Results and Business Results
* Reported a revenue of approximately USD 390 million, a 42.9% YoY increase, and a gross profit ofUSD 260 million, achieving YoY growth of 41.9%. * The Group's non-cell therapy business witnessed its fastest growth in five years with a net profit increase of more than 100%; while its cell ther...
Genscript Biotech Reports Full Year 2020 Financial Results
Highlights: * Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximatelyUS$273.4 million for the year ended December 31, 2019 * Gross profit of the Group for the year ended December 31, 2...
GenScript Signs a Strategic Partnership with the Theragen Etex and MedPACTO for Therapeutic Antibody Drug development
SINGAPORE, March 25, 2021 /PRNewswire/ -- A global leading biotech company GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) announced that the Company has entered into a strategic partnership with the Theragen Etex, a South Korea-based comprehensive pharmaceutical and biotechnology...
GenScript receives "Best Contract Research Organization Award" in the 4th Annual Asia-Pacific Bioprocessing Excellence Awards Ceremony 2021
SINGAPORE, March 16, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the "Best Contract Research Organization Award" on the 4th Annual Asia Pacific Bioprocessing Excellence Awards Ceremony 2021held on 16th March 2021. The award follows GenScri...
GenScript Submits Application with FDA for Use of cPass™ SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening
PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ -- GenScript USA Inc., the world's leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 N...
GenScript and InnoBation Enter into the Agreement for CAR-T therapy
NANJING, China and SEOUL, South Korea, Dec. 15, 2020 /PRNewswire/ -- A global leading biotech company GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) announces that it has reached the agreement for cell line development and engineering, manufacture service of GMP Plasmids and Len...
cPass(TM) SARS-CoV-2 Neutralization Antibody kit is the first EUA authorized test that detects neutralizing antibodies within one hour
SINGAPORE, Nov. 11, 2020 /PRNewswire/ -- Following GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK)'s cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit has received provisional authorization by Health Science Authority (HSA)Singapore on 8th May 2020, CE-IVD marking in Europ...
cPass(TM) SARS-CoV-2 Neutralization Antibody kit is the first EUA authorized test that detects neutralizing antibodies within one hour
SINGAPORE, Nov. 11, 2020 /PRNewswire/ -- Following GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK)'s cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit has received provisional authorization by Health Science Authority (HSA)Singapore on 8th May 2020, CE-IVD marking in Europ...
GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit
PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ -- GenScript USA Inc., the world's
leading research reagent provider, announced today that the U.S. Food and Drug
Administration (FDA) has grantedEmergency Use Authorization (EUA)
GenScript Biotech Corporation signs exclusive agreement with PH biotech firm to distribute faster, more accurate and more affordable immunity tests for COVID-19
SINGAPORE, Sept. 1, 2020 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) entered an exclusive partnership with Philippines biotech company, IP Biotech. ). This will allow the firm to distribute a breakthrough test kit designed to measure the levels of neutralizing...
GenScript Reports 2020 Interim Results and Provides Business Update
NANJING, China, Aug. 31, 2020 /PRNewswire/ -- GenScript Biotech Corp. (Stock Code: 1548.HK), a leading global biotechnology company, today reported interim results for the six months endedJune 30, 2020 and provided a corporate update. Revenue of the Group for the six months endedJune 30, 2020 was...
Duke-NUS, GenScript and A*STAR launch first-in-the-world SARS-CoV-2 serology test to detect neutralising antibodies without need of containment facility or specimen
* As a first-in-the-world "rapid smart test kit", the cPass™ which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficacy...
Duke-NUS, GenScript and A*STAR launch first-in-the-world SARS-CoV-2 serology test to detect neutralising antibodies without need of containment facility or specimen
* As a first-in-the-world "rapid smart test kit", the cPass™ which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficac...
GenScript ProBio and Eutilex Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for CAR-T Programs
NANJING, China and SEOUL, South Korea, April 7, 2020 /PRNewswire/ -- GenScript Biotech Corporation's CDMO business GenScript ProBio (hereinafter referred to as GenScript ProBio) and Eutilex Co., Ltd. (hereinafter referred to as Eutilex) committed to developing anti-cancer immunotherapy technology...
GenScript Biotech Reports 2019 Financial Results and Provides Business Update
NANJING, China, April 1, 2020 /PRNewswire/ -- GenScript Biotech Corp. (Stock Code: 1548.HK), a leading global biotechnology company, yesterday reported full year 2019 financial results and provided a corporate update. In 2019, overall revenue of the Group was approximatelyUS$273.4 million, repres...
GenScript and Selecxine Enter Into Strategic Cooperation Agreement
SEOUL, South Korea, Dec. 26, 2019 /PRNewswire/ -- On Dec. 23, 2019, at Seoul, South Korea, the CDMO segment of the world's leading biotech company GenScript announced that it signed a strategic collaboration agreement with Selecxine Inc., a Korean biotech company dedicated to novel therapeutics f...
China's Largest Plasmid and Virus Facility from GenScript was Put into Operation
ZHENJIANG, China, Dec. 20, 2019 /PRNewswire/ -- The CDMO segment of the world's leading biotech company GenScript announced that GenScript's plasmid and virus facility was put into operation onDecember 18, 2019. It is a milestone on the path to industrialization of the gene and cell therapy indus...
